Pharmacists authorized to prescribe, dispense, and administer drugs to prevent acquisition of human immunodeficiency virus; pharmacists authorized to order, conduct, and interpret laboratory tests necessary for therapy that uses drugs to prevent acquisition of human immunodeficiency virus.
Impact
HF2466 will implement changes in the state law concerning healthcare and pharmacy practices. It allows pharmacists to order, conduct, and interpret laboratory tests required for the therapies related to HIV prevention. By extending these responsibilities to pharmacists, the intent is to reduce barriers to obtaining essential medications, possibly leading to better health outcomes for populations at risk of HIV. The bill also proposes a standardized protocol for pharmacists, ensuring that they are adequately trained and supported in their roles.
Summary
House File 2466 aims to enhance the role of pharmacists in the prevention of HIV by authorizing them to prescribe and administer antiretroviral drugs. The bill emphasizes comprehensive coverage for these medications, mandating that health plans cannot impose step therapy protocols that would limit a patient's access to necessary treatments. The approach is designed to facilitate a more accessible healthcare framework for individuals at risk of HIV, promoting preventative measures such as pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP).
Contention
While the bill has garnered support from various public health advocates who view it as a step forward in combating HIV, it may face contention from within the healthcare community regarding the scope of pharmacist authority. Concerns have been raised about the potential for overstepping the traditional roles of pharmacists, leading to debates about patient safety and the adequacy of the proposed training for pharmacists. Opponents fear that the bill might allow pharmacists to operate in a space traditionally held by physicians, possibly leading to complications in patient management.
Prohibits Medicaid service providers from requiring prior authorization for antiretroviral prescription drugs for the treatment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
Prohibits Medicaid service providers from requiring prior authorization for antiretroviral prescription drugs for the treatment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
AN ACT to amend Tennessee Code Annotated, Title 4; Title 56 and Title 71, relative to the coverage of long-acting injectable drugs for the treatment or prevention of human immunodeficiency virus.
Payment rates established for certain substance use disorder treatment services, and vendor eligibility recodified for payments from the behavioral health fund.
Cover Outstanding Vulnerable Expansion-eligible Residents Now Act or the COVER Now Act This bill establishes a demonstration program to allow local governments to provide health benefits to the Medicaid expansion population in states that have not expanded Medicaid. Under the program, local governments may provide coverage for individuals who are newly eligible for Medicaid under the Patient Protection and Affordable Care Act (i.e., the Medicaid expansion population) for a maximum of 10 years, or until their respective states expand Medicaid. The bill provides a 100% federal matching rate for the first three years of program participation. The bill prohibits states from taking certain actions against participating localities, such as withholding funding, increasing taxes, or restricting provider participation. States that violate these requirements are subject to certain funding penalties.